Grants per year
Personal profile
Research Interests
I am dedicated to providing the high-quality and compassionate care for patients with breast cancer. I am interested in clinical research with a focus on developing clinical trials of novel agents for the treatment of all stages of breast cancer and investigating biomarkers to guide therapy decisions.
Training Experience
| 2014 | Residency, Northwestern University, McGaw Medical Center |
| 2018 | Fellowship, Northwestern University, McGaw Medical Center |
Education/Academic qualification
MD, Northwestern University, Feinberg School of Medicine
… → 2011
Fingerprint Dive into the research topics where Ami N Shah is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
- 3 Active
Prot #SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2−Breast Cancer with an ESR1 Mutat
Linical Americas, Sermonix Pharmaceuticals, Inc.
5/28/20 → 5/28/23
Project: Research project
Prot #BTCRC-BRE18-337: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
Hoosier Cancer Research Network, Inc., Pfizer Inc.
1/21/20 → 1/21/23
Project: Research project
Prot #ALT-002-SRE-01: A Phase I/II Dose Escalation Study of AP-002 In Patients with Advanced or Recurrent Solid Tumors
12/9/19 → 12/9/22
Project: Research project
Research Output
Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
Shah, A. N., Metzger, O., Bartlett, C. H., Liu, Y., Huang, X. & Cristofanilli, M., Jun 1 2020, In : Oncologist. 25, 6, p. e900-e908Research output: Contribution to journal › Review article
Open Access
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)
Gerratana, L., Zhang, Q., Shah, A. N., Davis, A. A., Zhang, Y., Wehbe, F., Qiang, W., Flaum, L., Finkelman, B. S., Gradishar, W. J., Platanias, L. C., Behdad, A. & Cristofanilli, M., Jan 2020, In : Critical Reviews in Oncology/Hematology. 145, 102856.Research output: Contribution to journal › Review article
Open Access
1
Scopus
citations
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., Rademaker, A., Nelson, V., Tsarwhas, D., Cristofanilli, M. & Gradishar, W., Feb 13 2020, In : Journal for immunotherapy of cancer. 8, 1, e000173.Research output: Contribution to journal › Article
Open Access
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
Davis, A. A., Zhang, Q., Gerratana, L., Shah, A. N., Zhan, Y., Qiang, W., Finkelman, B. S., Flaum, L., Behdad, A., Gradishar, W. J., Platanias, L. C. & Cristofanilli, M., Dec 4 2019, In : Breast Cancer Research. 21, 1, 137.Research output: Contribution to journal › Article
Open Access
2
Scopus
citations
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C. & Cristofanilli, M., Aug 1 2019, In : Current treatment options in oncology. 20, 8, 68.Research output: Contribution to journal › Review article
2
Scopus
citations